Drug class | Drug | Complications |
TNF-alpha inhibitors | Etanercept | Infectious |
Streptococcus pneumoniae |
Histoplasmosis |
Tuberculosis |
Noninfectious |
Systemic lupus erythematosus pleural disease |
Pulmonary fibrosis |
Granulomatous inflammation |
Pneumonitis |
Exacerbation of interstitial disease |
Infliximab | Infectious |
Tuberculosis |
Bovine tuberculosis |
Cryptococcosis |
Histoplasmosis |
Legionellosis |
Invasive and allergic aspergillosis |
Scedosporium infection |
Actinomycosis |
Pneumocystis jirovecii |
Coccidioidomycosis |
Noninfectious |
Langerhans cell histiocytosis |
Drug-induced alveolitis |
Systemic lupus erythematosus pleural or parenchymal disease |
Sarcoidosis |
Interstitial pneumonitis |
Diffuse alveolar hemorrhage |
Fibrosing alveolitis |
Adalimumab | Infectious |
Tuberculosis |
Aspergillosis |
Noninfectious |
Pulmonary fibrosis |
IL-1 inhibitor | Anakinra | Infectious |
Tuberculosis |
Costimulation blockade | Abatacept | Infectious |
Bacterial pneumonia |
B-cell depletion | Rituximab | Noninfectious |
Interstitial pneumonitis |
Pulmonary fibrosis |